Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Randomized Study of Trastuzumab Combined With Chemotherapy or Endocrine Therapy as the First Line Treatment for Patients With Metastatic Luminal B2 Breast Cancer Subtype

NCT01950182 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT01950182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01950182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Randomized Study of Trastuzumab Combined With Chemotherapy or Endocrine Therapy as the First Line Treatment for Patients With Metastatic Luminal B2 Breast Cancer Subtype
Lead sponsor
Sun Yat-sen University
Phase
Phase 3
Overall status
Completed
Start date
September 16, 2013
Completion date
May 31, 2020
Enrollment
392 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer